Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1549416 | 0.78 | PPARD (0.47) | PPARDFNTAFNTBPGGT1BTSHR | |
| SCHEMBL1131627 | 0.75 | PPARD (0.44) | PPARDMMP1MMP2FNTAFNTB | |
| SCHEMBL2326336 | 0.72 | PPARD (0.41) | PPARDMMP1MMP2FNTAFNTB | |
| SCHEMBL27769745 | 0.72 | LIPA (0.32) | — | |
| SCHEMBL10681801 | 0.70 | METAP1 (0.36) | MMP1MMP2TSHR | |
| SCHEMBL4936680 | 0.70 | PPARD (0.39) | PPARDMMP1MMP2FNTAFNTB | |
| SCHEMBL4940540 | 0.70 | PPARD (0.39) | PPARD | |
| SCHEMBL1549162 | 0.69 | PPARD (0.50) | PPARDFNTAFNTBPGGT1BTSHR | |
| SCHEMBL3939836 | 0.69 | PPARD (0.41) | PPARDMMP1MMP2FNTAFNTB | |
| SCHEMBL4943149 | 0.68 | PPARD (0.37) | PPARDMMP1MMP2FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044034-B1 | ALKYL-PYRIDAZINE DERIVATIVES AS INHIBITORS OF 11 BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1(11B-HSD 1) | HOFFMANN LA ROCHE (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-7547697-B2 | Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-06-16 | — | — | US | disclosed |
| EP-2044034-A1 | ALKYL-PYRIDAZINE DERIVATIVES AS INHIBITORS OF 11 BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1(11B-HSD 1) | F. Hoffmann-Roche AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008003611-A1 | ALKYL-PYRIDAZINE DERIVATIVES AS INHIBITORS OF 11 BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1(11B-HSD 1) | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009499-A1 | Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009499-A1 | Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | PPARD 334/4885MMP1 492/4885MMP2 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.